Buy Tickets for Mapping the Mind 2019 Conference and all our side events
Mendel Kaelen, PhD is a psychedelic researcher, neuroscientist and founder and CEO of Wavepaths. At Imperial College London he studied brain mechanisms and use of music in psychedelic therapies. Within Wavepaths Mendel leads a growing team of scientists, artists, therapists and technologists to develop a new category of accessible psychotherapeutic tools and environments that leverage the psychotherapeutic potential of music for/as psychedelic therapy.
David E. Nichols is a pharmacologist and medicinal chemist, previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University. He has worked in the field of psychedelic science since 1969, published over 280 papers on the topic, and personally synthesized a number of novel psychedelic compounds. David is the founding president of the Heffter Research Institute, one of the main driving forces behind the psilocybin research at Johns Hopkins University and NYU.
Matthew W. Johnson, Ph.D., Associate Professor of Psychiatry at Johns Hopkins University School of Medicine, is a leading expert on the effects of psychedelics. He is an experimental psychologist with expertise on psychoactive drugs and the psychology of addiction and risk behavior. Matt has received >8 million US dollars in research funding as principal investigator from the US National Institutes of Health and non-profit foundations.
For 20 years he has conducted academic research in psychopharmacology and addictions, and for 14 years he has conducted human research with psychedelics. He has published >100 articles and chapters, with over a third focused on psychedelics. Matt published safety guidelines for human psychedelic research in 2008, which facilitated safe initiation of psychedelic research at a growing number of universities. He has served as guide for >100 psychedelic sessions.
Srinivas Rao is the Chief Scientific Officer at ATAI Life Sciences AG and the former CEO of Kyalin Biosciences.
Srinivas Rao has been the Chief Medical Officer of multiple biotech companies, including Axial Biotheraputics, Inc., Deposed, Inc. and Kayla Pharmaceuticals. He holds an MD in Internal Medicine from Yale University School of Medicine and a PhD in Neuropharmacology from Yale University. Srinivas has also been an advisory board member to UCSD SDTA and HUYA Bioscience international.
Bruce Tobin received his doctorate from the University of Washington, specializing in philosophy of psychology. He has been in private practice psychotherapy for 35 years, specializing in the treatment of anxiety, depression and emotional trauma. He taught clinical skills for 25 years at the University of Victoria, where he was Adjunct Assistant Professor and a member of the Graduate Faculty. He worked under contract with Health Canada for 20 years providing psychological services to First Nations communities in the Victoria area.
Bruce is the Program Director of TheraPsil, a group of health professionals who aim to make psilocybin-assisted treatment legal for end-of-life anxiety in cancer patients in Canada.
Paul Lewin is a cannabis lawyer in Toronto who has litigated a vast array of cannabis issues. Paul has litigated the constitutionality of the doctor-as-gatekeeper requirement, patient access to cannabis by mail-order, and the prohibition on the religious use of cannabis. Paul challenged and ended the police practise of accessing hydro consumption records without warrant in order to raid cannabis gardens. Paul has been practising in Toronto for almost 25 years. He is also a long time board member for NORML Canada.
Paul is working pro bono on TheraPsil’s case to legalize medicinal psilocybin for end-of-life cancer patients in Canada.
Rotem Petranker is a PhD student at York University and the Associate Director of the new Center for Psychedelic Studies at the University of Toronto. As part of the team at CPS, Rotem plans to conduct a controlled study on the effects of microdosing, measuring constructs including creativity, wellbeing, mindfulness, and intelligence. Rotem also spoke at last year’s Mapping the Mind, about the first microdosing study ever conducted.
Dr. Emma Hapke is an attending psychiatrist at the Centre for Addiction and Mental Health in Toronto, Ontario, and a lec- turer at the University of Toronto. Her specialty is in women’s mental health and the treatment of developmental trauma, sexual trauma, and complex PTSD. She has extensive training in multiple modalities of psychotherapy and has worked clinically with ketamine-assisted psychotherapy. She is joining the MAPS research team as the Clinical Investigator at the Montreal site for Phase 3 and in developing a study in Toronto combining Cognitive Processing Therapy (CPT) with MDMA .
Ron spent 23 years working in community health, harm reduction and addiction prior to embarking on his PhD research. He has taught at Queen’s University for 14 years, and oversees the Dēlos Psychedelics Learning Lab. While his research is specific to psilocybin and it’s potential role in treating mood, self-regulatory disorders and end of life anxiety, he is a student of plant medicine and consciousness in general, with a specific interest in shamanism and the cultural anthropology of psychoactive plant use.